Plain-English translation of NCT03866408 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Obesity research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers want to understand why some people's bodies struggle to control how fat is broken down, especially in the belly area. This trial tests whether a medication called , combined with a weight loss program, can help the body better regulate fat breakdown. The study will compare people who start a lifestyle weight loss program right away with those who wait, and some participants will also receive the medication.
People with obesity often have problems with how their bodies regulate fat breakdown, which may make weight loss harder. Researchers hope that this medication, which affects fat cells directly, could help restore the body's natural ability to control fat breakdown and improve treatment outcomes.
You likely qualify if…
You likely don't qualify if…
You will have baseline tests to measure how your body breaks down fat. Then, depending on which group you're assigned to, you might start a comprehensive weight loss program right away (with either the medication or a placebo pill), or wait 4 months while being monitored, then begin the program. Throughout the study, you'll have follow-up visits to measure changes in your fat cells and overall health.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Mayo Clinic
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrollment target
~64 participants
Started
November 2018
Primary completion
December 2026
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in January 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.